Altimmune | 8-K: FY2026 Q2 Revenue Meets Estimate at USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0, meeting the estimate of USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.12, beating the estimate of USD -0.1385.

EBIT: As of FY2026 Q2, the actual value is USD -21.73 M.

Financial Position and Cash, Cash Equivalents, and Investments

Altimmune, Inc. reported total cash, cash equivalents, and investments of $519 million as of June 30, 2026, which included cash and cash equivalents of $63,008 thousand, short-term investments of $263,273 thousand, and long-term investments of $192,247 thousand. This compares to $43,760 thousand in cash and cash equivalents, $229,696 thousand in short-term investments, and no long-term investments as of December 31, 2025. Total assets increased to $527,212 thousand as of June 30, 2026, from $279,929 thousand as of December 31, 2025. Total liabilities decreased to $53,004 thousand as of June 30, 2026, from $55,037 thousand as of December 31, 2025. Total stockholders’ equity significantly increased to $474,208 thousand as of June 30, 2026, from $224,892 thousand as of December 31, 2025.

Public Offering Proceeds

In April 2026, Altimmune, Inc. completed a public offering of common stock, pre-funded warrants, and stock warrants, generating gross proceeds of $225.0 million.

Research and Development (R&D) Expenses

R&D expenses for the three months ended June 30, 2026, were $18,655 thousand, an increase from $17,236 thousand in the same period in 2025, primarily due to ongoing ALD trial and PERFORMA Phase 3 MASH trial startup costs. For the six months ended June 30, 2026, R&D expenses totaled $34,847 thousand, compared to $33,063 thousand in the prior year period.

General and Administrative (G&A) Expenses

G&A expenses were $7,574 thousand for the three months ended June 30, 2026, up from $5,691 thousand for the same period in 2025, mainly driven by increased professional services and compensation. For the six months ended June 30, 2026, G&A expenses were $15,626 thousand, versus $11,684 thousand for the six months ended June 30, 2025.

Interest Income

Interest income for the three months ended June 30, 2026, was $4,526 thousand, significantly higher than $1,132 thousand in the corresponding period of 2025. For the six months ended June 30, 2026, interest income was $7,427 thousand, compared to $2,677 thousand in the prior year period.

Net Loss

Altimmune, Inc. reported a net loss of - $22,825 thousand for the three months ended June 30, 2026, compared to a net loss of - $22,146 thousand for the same period in 2025. The net loss for the six months ended June 30, 2026, was - $45,388 thousand, compared to - $41,721 thousand in the prior year period.

Comprehensive Loss

Comprehensive loss for the three months ended June 30, 2026, was - $23,639 thousand, compared to - $22,182 thousand for the same period in 2025. For the six months ended June 30, 2026, comprehensive loss was - $46,498 thousand, versus - $41,787 thousand for the six months ended June 30, 2025.

Operational Highlights

Altimmune, Inc. initiated the global PERFORMA Phase 3 MASH trial in August 2026, and pemvidutide received Breakthrough Therapy Designation from the FDA for MASH. In July 2026, the company reported positive topline results from the RECLAIM Phase 2 trial of pemvidutide in Alcohol Use Disorder (AUD), achieving a statistically significant reduction in heavy drinking days, and the FDA granted Fast Track designation for AUD. Patient enrollment was completed in the RESTORE Phase 2 trial of pemvidutide in Alcohol-associated Liver Disease (ALD) in July 2026.

Outlook / Guidance

Altimmune, Inc. anticipates a 52-week data readout for the PERFORMA Phase 3 MASH trial in 2029. The company plans to request an End-of-Phase 2 meeting with the FDA and engage with European regulatory agencies to discuss the path forward for pemvidutide in AUD. Topline data for the RESTORE Phase 2 ALD trial is expected to be reported in the second half of 2027.